Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

被引：87

作者：

Choi, Michael Y. ^{[1
]}

Widhof, George F., II ^{[1
]}

Wu, Christina C. N. ^{[1
]}

Cui, Bing ^{[1
]}

Lao, Fitzgerald ^{[1
]}

Sadarangani, Anil ^{[1
,2
]}

Cavagnaro, Joy ^{[3
]}

Prussak, Charles ^{[1
]}

Carson, Dennis A. ^{[1
]}

Jamieson, Catriona ^{[1
,2
]}

Kipps, Thomas J. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Div Regenerat Med, La Jolla, CA 92093 USA

[3] Access Bio, Boyce, VA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷

基金：

美国国家卫生研究院;

关键词：

AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN ROR1; EXPRESSION; RECEPTOR; PSEUDOKINASE; PHENOTYPE; FAMILY; CLL;

D O I：

10.1016/j.clml.2015.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.

引用

页码：S167 / S169

页数：3

共 50 条

[1] Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts
Choi, Michael Y.
Widhopf, George F., II
Castro, Januario
Li, Hongying
Kidwell, Reilly L.
Zhang, Sam C.
Juarez, Tiffany
Gorak, Susette
Rassenti, Laura Z.
Messer, Karen
Prussak, Charles
Jamieson, Catriona H. M.
Kipps, Thomas J.
BLOOD, 2015, 126 (23)
[2] Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1
Cui, Bing
Widhopf, George F., II
Yu, Jian
Martinez, Daniel
Avery, Esther
Zhang, Suping
Chen, Liguang
Wu, Rongrong
Wu, Christina C. N.
Prussak, Charles
Kipps, Thomas J.
BLOOD, 2011, 118 (21) : 450 - 450
[3] Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)
Yu, Jian
Chen, Liguang
Widhopf, George F., II
Zhang, Suping
Cui, Bing
Wu, Rongrong
Zhang, Ling
Kipps, Thomas J.
BLOOD, 2015, 126 (23)
[4] Pre-Clinical Development of a First in Class Half-Life Extended T Cell Engager Targeting ROR-1
Granger, David
Henne, Patricia
Baccaro, Annalisa
Fernando, Dinusha
Gore, Jasmine
Gbajumo, Ephraim
Muczynski, Vincent
Shah, Mittal
O'Donovan, Kieran
Chester, Kerry
Nathwani, Amit C.
BLOOD, 2022, 140 : 7810 - 7811
[5] Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP
Higgins, Catherine A.
Fox, Jennifer
Majkut, Joanna
Fiedler, Greti E.
Roberts, Jamie
Humphreys, Luke
Boffey, Ray J.
Perrior, Trevor R.
Harrison, Timothy
Longley, Daniel B.
CANCER RESEARCH, 2019, 79 (13)
[6] Targeting Human B Cell Chronic Lymphocytic Leukemia With a Monoclonal Antibody Specific for the Receptor Tyrosine Kinase ROR1
Baskar, Sivasubramanian
Yang, Jiahui
Rader, Christoph
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 969 - 969
[7] Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1
Cranston, Aaron N.
Wappett, Mark
McLean, Estelle G.
Saladino, Chiara
McCann, Aidan
Kung, Wei-Wei
Thom, Jennifer
Trumper, Paul
Porter, Andy
Barelle, Caroline
Harrison, Tim
Cotton, Graham
CANCER RESEARCH, 2024, 84 (07)
[8] Development of a first-in-class humanized antibody targeting CXCL1 in bladder cancer
Murakami, Kaoru
Sasaki, Yuka
Furuya, Hideki
Rosser, Charles
CANCER RESEARCH, 2022, 82 (12)
[9] DEVELOPMENT OF A FIRST-IN-CLASS HUMANIZED ANTIBODY TARGETING CXCL1 IN BLADDER CANCER
Murakami, Kaoru
Sasaki, Yuka
Furuya, Hideki
Rosser, Charles
JOURNAL OF UROLOGY, 2021, 206 : E729 - E729
[10] Pre-clinical development of a first-in-class heat shock protein-based personalized cancer vaccine
Khattar, M.
Morin, B.
Uduman, M.
Zelin, J.
Stein, R.
Exley, M.
Castle, J.
Levey, D.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 221 - 221

← 1 2 3 4 5 →